Carmelo Marco Giacchetto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carmelo Marco Giacchetto has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Calogero Cammà
Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy
2 shared publications - Caterina Stornello
Section of Gastroenterology and Hepatology Department of Health Promotion, Mother and Child Care Internal Medicine and Medical Specialties PROMISE University of Palermo Palermo Italy
2 shared publications - Ciro Celsa
Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, 90133 Palermo, Italy
2 shared publications - Gabriele Rancatore
Gastroenterology and Hepatology, IRCCS-ISMETT (Mediterranean Institute for Transplantation and Advanced Therapies), 90127 Palermo, Italy
2 shared publications - Giuseppe Cabibbo
Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy
2 shared publications - Mauro Grova
Endoscopy Unit, “Villa Sofia-Cervello” Hospital , Palermo
2 shared publications
Latest Publications
- 21 March 2022
- Published by Elsevier in Digestive and Liver Disease
- Vol. 54, S52-S53
Outcomes of three lines Atezolizumab plus Bevacizumab-based sequential treatment for hepatocellular carcinoma: a simulation model
- 21 March 2022
- Published by Elsevier in Digestive and Liver Disease
- Vol. 54, S52-S53
Outcomes of three lines Atezolizumab plus Bevacizumab-based sequential treatment for hepatocellular carcinoma: a simulation model
- Open Access
- 12 October 2021
- Published by Wiley in Liver Cancer International
- Vol. 2 (3) , 82-95
Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma
The number of effective systemic therapies for the treatment of unresectable hepatocellular carcinoma (uHCC) is rapidly increasing and the advent of immunotherapy changed the treatment paradigm for these patients, leading to a significant improvement in survival outcomes. While sorafenib, a tyrosine‐kinase inhibitor monotherapy, remained the only effective treatment for almost a decade, the combination of atezolizumab, an immune checkpoint inhibitor (ICI) targeting programmed death‐ligand 1, plus bevacizumab, an antiangiogenic agent targeting vascular endothelial growth factor, now represents the new standard of care for patients with uHCC. Moreover, several further clinical trials are ongoing to evaluate novel combinations between ICIs with other drugs, belonging to the same class or to other classes. As HCC occurs in most cases in the setting of cirrhosis, the evaluation of the risk/benefit ratio of systemic treatments represents a critical point. The underlying liver disease significantly influences the safety and the effectiveness of current and future systemic treatments for uHCC. For this reason, the hepatotoxicity profile and impact on liver function of these molecules should be carefully assessed in both clinical trials and in the real‐world setting. Here, we review hepatotoxicity data on systemic treatments for uHCC and offer suggestions on monitoring and managing liver‐related adverse events occurring during the treatment.
- 12 October 2021
- Published by Wiley in Liver Cancer International
- Vol. 2 (3) , 82-95
Open AccessHepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma
The number of effective systemic therapies for the treatment of unresectable hepatocellular carcinoma (uHCC) is rapidly increasing and the advent of immunotherapy changed the treatment paradigm for these patients, leading to a significant improvement in survival outcomes. While sorafenib, a tyrosine‐kinase inhibitor monotherapy, remained the only effective treatment for almost a decade, the combination of atezolizumab, an immune checkpoint inhibitor (ICI) targeting programmed death‐ligand 1, plus bevacizumab, an antiangiogenic agent targeting vascular endothelial growth factor, now represents the new standard of care for patients with uHCC. Moreover, several further clinical trials are ongoing to evaluate novel combinations between ICIs with other drugs, belonging to the same class or to other classes. As HCC occurs in most cases in the setting of cirrhosis, the evaluation of the risk/benefit ratio of systemic treatments represents a critical point. The underlying liver disease significantly influences the safety and the effectiveness of current and future systemic treatments for uHCC. For this reason, the hepatotoxicity profile and impact on liver function of these molecules should be carefully assessed in both clinical trials and in the real‐world setting. Here, we review hepatotoxicity data on systemic treatments for uHCC and offer suggestions on monitoring and managing liver‐related adverse events occurring during the treatment.
- Open Access
- 24 April 2009
- Published by Hindawi Limited in Andrologia
- Vol. 15 (4) , 374-379
Testosterone and Dihydrotestosterone Seminal Plasma Levels in Varicocele Patients
Testosterone (T) and Dihydrotestosterone (DHT) were measured in seminal plasma levels of forty-four varicocele patients and in seventeen normal men. T values were not significantly different from controls, while DHT values were significantly lower in varicocele patients. When we grouped the patients according to the sperm count, we observed a decrease of DHT similar to that reported by other authors in oligozoospermic patients. However in the patients with normal sperm count, where the motility was the only parameter significantly lower, DHT in the ejaculate showed again a marked decrease. In contrast to that observed in the normal subjects, in the latter group, with normal sperm count, we observed a negative correlation between the age of the patients and DHT in the ejaculate. This suggests that the duration of varicocele per se could affect DHT seminal plasma levels.
- 24 April 2009
- Published by Hindawi Limited in Andrologia
- Vol. 15 (4) , 374-379
Open AccessTestosterone and Dihydrotestosterone Seminal Plasma Levels in Varicocele Patients
Testosterone (T) and Dihydrotestosterone (DHT) were measured in seminal plasma levels of forty-four varicocele patients and in seventeen normal men. T values were not significantly different from controls, while DHT values were significantly lower in varicocele patients. When we grouped the patients according to the sperm count, we observed a decrease of DHT similar to that reported by other authors in oligozoospermic patients. However in the patients with normal sperm count, where the motility was the only parameter significantly lower, DHT in the ejaculate showed again a marked decrease. In contrast to that observed in the normal subjects, in the latter group, with normal sperm count, we observed a negative correlation between the age of the patients and DHT in the ejaculate. This suggests that the duration of varicocele per se could affect DHT seminal plasma levels.